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net searches of relevant websites (such as different health technology assessment 
agencies in Europe). Researchers conducted discussions with payers and biopharma 
experts to identify the perceived differences in pricing negotiations between coun-
tries. RESULTS: There are distinctive differences in the approaches to pricing nego-
tiations between payers in the US and Europe. These lead to determinable patterns 
in the methods that biopharma companies leverage to price their products and in 
the methods that payers use, by either working with the biopharma companies or 
creating reimbursement mechanisms to guide the appropriate utilization of these 
products. European payers have more central negotiating leverage and more for-
malized health technology assessments, which enable them to negotiate and even 
mandate prices and/or develop outcome-based contracts. CONCLUSIONS: Unlike 
European payers, most US payers do not have the support of similar government-
backed organizations for negotiating price, and most cannot optimally leverage 
health technology assessments. This forces US payers to seek more creative ways of 
managing the utilization of products through medical policies, prior authorizations 
and creative reimbursement methods.
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OBJECTIVES: Prices of medicines differ across EU Member States due to factors, 
some of which are beyond responsibilities of companies. These differences include: 
wholesaler or pharmacy margins, sales tax, pack sizes, distribution channels, 
exchange rate fluctuations, and perhaps most importantly, price-setting processes, 
but also national health and pharmaceutical policies and priorities. Current EU 
transfer pricing rules only address process rather than the resulting levels of pric-
ing and reimbursement. Member States compare and reference price with each 
other (so called ‘International Reference Pricing’ or IRP). We aim to demonstrate 
that companies need to employ a range of different mechanisms to mitigate the 
effects of IRP. METHODS: We review how legislation and case law, including that 
relating to parallel trade or grey market, reinforces national rights to set prices. 
Current price constraints and their interpretation are considered. We then consider 
forthcoming proposals and the extent to which they may lead to greater pricing 
consistency. RESULTS: Based on a review of all nine cases that have proceeded to 
the EU courts, the principle of EU member state discretion in terms of price set-
ting seems currently sacrosanct and it is unlikely that the legislators will be able 
to change this position. In order to balance the respective interests of the industry 
and member states, member states should allow differential pricing; restrict IRP to 
economically comparable Member States; exclude from IRP those elements related 
to pharmaceutical regulation and policies, which are country-specific and likely to 
distort price comparisons; and exclude from IRP and free movement provisions, 
those countries under austerity measures. CONCLUSIONS: Currently, manufac-
turers have limited strategies in terms of price corridors and the like; it seems 
therefore, that more pragmatic solutions will need to be considered at an EU level 
and supported by the Courts.
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OBJECTIVES: In the absence of randomized controlled trials (RCTs) for informing 
clinical effectiveness, manufacturers need to rely on alternative methods for the 
generation of clinical evidence for HTA purposes. As the body of evidence based on 
observational study designs grows, there is a need to understand whether and how 
non-randomized evidence can be incorporated into HTAs globally. The aim of this 
study was to collate and compare published HTA guidance on the use and accept-
ance of non-randomized evidence to inform clinical effectiveness. METHODS: 
Guidelines referring to methods for economic evaluation in the UK, Ireland, 
Australia, Canada, and Germany, were searched for information on the use of non-
randomized evidence to demonstrate clinical effectiveness. Technology appraisals 
and reports from evidence review groups (ERGs) (published 2004–2014) in the oncol-
ogy setting, were assessed to identify circumstances in which non-randomized evi-
dence was submitted in HTAs, and to understand how this evidence was considered 
by ERGs. RESULTS: A lack of clear guidance was found regarding when and how 
non-randomized evidence can be used to support HTAs. Although the majority of 
HTAs request that a systematic search for non-RCT data be conducted, few HTAs 
considered non-randomized evidence relevant to clinical effectiveness outcomes. 
Observational data were submitted to HTA bodies in order to: complement and 
extrapolate RCT evidence, test the integrity of evidence synthesis networks, and 
inform long-term safety outcomes. Feedback regarding the appropriateness of 
observational data was minimal or absent in many ERG reports. CONCLUSIONS: 
There is a need for HTA bodies to provide clearly defined guidance regarding the 
use and appropriateness of observational data for HTA purposes. Currently, there 
is no clear consensus on the value that non-randomized evidence can offer from 
a HTA perspective.
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OBJECTIVES: The study aims to assess the perspectives of different healthcare 
stakeholders on the current incremental cost-effectiveness ratio (ICER) thresh-
olds and understand if these are still considered appropriate for their intended 
model was employed to estimate factors associated with where a new drug was 
reimbursed by NHI and its reimbursement lag. RESULTS: We found that for new 
drugs in Taiwan, the median of marketing lag was 26.84 month while the median of 
reimbursement lag was 11.83 months. About 84% of new drugs were reimbursed by 
NHI. The reimbursement decision were mainly associated with the characteristics 
of medications, including their types of therapy and innovation categories. The 
price-related factors were significantly related with the reimbursement lag but not 
whether medications were reimbursed. CONCLUSIONS: By examining the barriers 
at different stages from drug approval to NHI reimbursed, this study provided dif-
ferent perspectives for health policy makers to examine issues on drug approval, 
health care resource allocation, and quality of medical care.
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OBJECTIVES: In Germany, the reimbursement and pricing of innovative in-patient 
drugs and devices is managed through the NUB application process. These applica-
tions are submitted by the hospital stakeholder and are approved or rejected by the 
Institute for the Hospital Remuneration System (InEK). The objective of this research 
was to assess the NUB trends in Germany in 2012-2014. METHODS: We developed 
a database of NUB approvals and rejections based on the Institute for the Hospital 
Remuneration System’s (InEK )’s reports. All information was extracted into Excel 
format. The following data was extracted: product name, indication, year of submis-
sion, number of NUB applications submitted, status score, type of evidence available 
and lack of evidence for NUB rejection. Additionally, the number of re-applications 
and re-rejections were also analyzed. RESULTS: In 2013 and 2014, a total of 21264 
and 25634 NUB applications were submitted for 612 and 613 medical products, 
respectively. Of these applications in 2013 and 2014, 10% and 16% were approved 
for NUB (as Status 1) and 82% and 75% were rejected (as Status 2), respectively. In 
2014, the median number of hospital applications for NUBs with Status 1 and Status 
2 were 37 and 3, demonstrating the importance of hospital participation for seek-
ing NUB approval. Among approved NUBs, 37% of the applications were for drugs 
and 63% were for devices. Interestingly, the median NUB hospital applications for 
approved drugs was 192, while for devices, the median was 9 applications. In 2014, 
447 NUB applications for products were re-submitted, of which 5 were approved and 
the remaining were re-rejected. The evidence requirements analysis suggests the 
need for hospital focused economic data. CONCLUSIONS: The NUB process plays 
a critical role in market access for in-patient drugs and devices. For approval, two 
key components are: hospital focused economic evidence and provider stakeholder 
involvement.
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OBJECTIVES: International Reference Pricing (IRP) is a key cost-containment tool 
for health care payers across the world. IRP may apply either fixed or flexible rules 
to calculate the price of branded drugs. Typically there is no negotiation between 
manufacturers and the IPR body. In the context of the German AMNOG price negotia-
tions and the role of Germany as a key referenced country, there is dearth of real-life 
evidence on the international impact of the AMNOG law. METHODS: The publicly 
available IRP rules were screened and evaluated systematically. Based on these find-
ings an IRP model was developed to simulate scenarios of price agreements for a 
new drug between the German Head Association of the Statutory Health Insurance 
Companies and the manufacturer. The impact of the price agreement on other coun-
tries was analyzed based on the existing IRP rules. RESULTS: We simulated a hypo-
thetical price dataset for a branded drug X with all prices set at 100 euro to limit the 
impact to Germany only. A 25% price drop in Germany would lead to a range of 32.5% 
reduction in Egypt and almost 1% in Austria. The largest impact in Europe would 
be in France, Romania, Russia, Slovenia, Luxembourg (-25%), followed by Norway 
and Greece (-8.33%), the Netherlands (-6.25%), Switzerland, Ireland and Denmark. A 
price drop of 50% in Germany would double the impact with the exception of Egypt 
(-55%). However, a limited impact was observed if the price increase in Germany was 
25%.That would lead to 6.25% increase in the Netherlands, 4.17% in Switzerland, 
2.78% in Ireland and Denmark, and about 1% increase in Austria. CONCLUSIONS: 
Price negotiations in Germany could potentially impact the price of new branded 
therapies in other countries. This could ultimately lead to a price-downward spiral 
with a negative impact on innovation and drug development in Europe.
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OBJECTIVES: In recent years, the pharmaceutical industry has received approval 
in the US and Europe for several products that are unique, meet previously unmet 
needs, and yield important reductions in mortality and morbidity. Frequently, these 
products are orphan and even ultra-orphan drugs targeted at very small patient 
populations. It is common for these products to be priced up to $500,000 per annum. 
This research reviewed the pricing of these unique products (including trends) and 
explored alternative funding strategies that have been negotiated (e.g. outcome 
contracts) and/or are being proposed (e.g. reimbursement methods) by payers to 
manage their budgets. METHODS: We conducted research on the publicly available 
data on unique biopharma products and their pricing through literature and inter-
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OBJECTIVES: Many key pharmaceutical markets (including England, Scotland, 
Canada and Australia) have Health Technology Assessment (HTA) bodies for which 
cost-utility analyses are key criteria. For such bodies, acceptable cost per Quality-
Added Life Year (QALY) based on the manufacturer’s submitted price must be dem-
onstrated. By contrast, in other major markets (such as France and Germany), a level 
of added benefit is ascribed to a drug and based upon this a price is negotiated. 
However, the expansion of international reference pricing means that prices in 
major ex-US markets are increasing converging. Thus the major difference between 
such agencies becomes the coverage, which this research compares, using the exam-
ple of 2 recent high cost breast cancer therapies. METHODS: Publically available HTA 
reports for Kadcyla and Perjeta from the pan-Canadian Oncology Review (pCODR), 
National Institute for Health and Care Excellence (NICE), Scottish Medicine Council 
(SMC), Institute for Quality and Efficiency in Healthcare (IQWiG, Germany), Haute 
Autorite de Sante (HAS, France), and Australian Pharmaceutical Benefits Advisory 
Committee (PBAC) were screened (up to December 2014) and the decision, date 
and key rationale were extracted. RESULTS: NICE, SMC, PBAC, and pCODR have all 
appraised both Kadcyla and Perjeta but none of these bodies have found either of 
these drugs to be cost-effective. By contrast, HAS and IQWiG have both appraised 
Kadcyla and Perjeta, granted coverage and found these to offer an added benefit 
compared to existing standard of care, thus securing it a negotiated premium over 
comparator therapies. CONCLUSIONS: Obligatory cost-utility bodies assess cost-
effectiveness based on the manufacturer’s price, which is often deemed not cost-
effective, resulting in frequent delays and denials to access of innovative products. 
However, if cost-utility bodies instead confidentially evaluated the QALY benefit and 
determined the proposed price based on this they could achieve potentially much 
better coverage without compromising their cost-utility principles.
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OBJECTIVES: Almost every Central Asian (CA) country, regulatory and reimburse-
ment authorities increasingly require pharmacoeconomic evaluation, as part of a 
formulary listing or reimbursement submission. A budget impact analysis (BIA) 
estimates fiscal consequences of adopting a new health technology or interven-
tion within a specific health context. Rapid benefit assessment (RBA) as a basis 
for central price regulation planned to introduce for new drugs in Kazakhstan. The 
objective was to investigate the converging trends in the BIA requirements in the 
CA countries and to compare them with the situation in Kazakhstan. METHODS: 
We conducted a survey of requirements for the pricing and reimbursement process 
of pharmaceuticals in 5 countries (Kazakhstan, Tajikistan, Kyrgyzstan, Uzbekistan, 
Turkmenistan). Where needed informal stakeholder interviews were used to sup-
plement lacking information. RESULTS: Increasing accessibility and affordability 
of healthcare services have been considered as important policy objectives in 
Kazakhstan. In the recent years, because a vast national drug formulary and state 
benefit outpatient drug program, there are problems with drug provision, cost of 
medical expenditure is rapidly growing and becoming increasingly unaffordable. 
Opportunities in all CA countries result from increasing affluence and life expec-
tancy and the diseases associated with these. Some challenges to market access 
are: poor IP protection, protectionist measures, compulsory licensing, drive to use 
generics or biosimilars, often produced locally, price controls, variable health insur-
ance/NHS coverage, and limited budgets for prescription drugs. Although demand 
for new drugs is increasing in these markets, protectionism measures, competition 
from generics and budget constraints due to the increased burden and requirement 
for new high priced drugs present a challenge when accessing the pharmaceutical 
market in CA countries. CONCLUSIONS: All of the investigated countries request no 
BIA from a payers perspective the drugs impact on the change in medical resource 
consumption is analyzed as part of the pharmacoeconomic and comparative effec-
tiveness analyses.
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OBJECTIVES: To examine the association between gender and CAM use among adults 
with multiple chronic conditions (MCC). METHODS: This study used a cross-sectional 
design with data from 2012 National Health Interview Survey. CAM use was meas-
ured using 18 variables. Type of CAM use consisted of alternative medical systems, 
mind-body therapy, and manipulative-body-based therapy. The relationships between 
gender and CAM use and types of CAM use were assessed with chi-square tests 
and logistic and multinomial logistic regressions. Separate logistic regression and 
multinomial logistic regressions among women and men were performed to assess 
the factors that are associated with CAM use in each group. RESULTS: Overall, 51.5% 
women and 44.3% men reported ever using CAM; in the past 12 months, 27.6% women 
and 18.9% men used CAM. Across all types of CAM, higher percentages of women 
than men used CAM. After controlling for demographic, socio-economic, health and 
lifestyle factors, women were more likely to report ever using CAM (AOR= 1.49; 95% 
CI [1.35, 1.65]) compared to men. Separate multinomial regressions of CAM use in the 
past 12 months revealed that the factors associated with CAM use were different for 
men and women. Women with both physical and mental health conditions were more 
likely to use CAM in the past 12 months (AOR= 1.38; 95% CI [1.17, 1.64]) compared to 
those with only physical conditions; but no such relationship was found in men. The 
relationship between age and type of CAM use was significant for women and not 
for men. CONCLUSIONS: Among individuals with MCC, women were more likely to 
purpose. METHODS: An electronic quantitative survey was administered to 150 
attendees of the 17th ISPOR European Congress in Amsterdam, Netherlands, in 
November 2013, using a random sampling method. The respondents included 
representatives from academia, industry, consulting firms, clinicians, and public/
government agencies. RESULTS: Respondents identified the five most important 
attributes driving positive reimbursement as: cost-effectiveness, quality of life, clini-
cal efficacy, budget impact, and therapeutic innovativeness. Almost all respondents 
(91.3%) believe ICER thresholds should be used to evaluate new health technolo-
gies (formally or informally). Approximately 75.9% believe that ICER thresholds 
should increase beyond the current value of £30,000/QALY. The average suggested 
threshold is £51,274/QALY, regardless of therapeutic area. For a disease with high 
clinical unmet need, respondents suggest an average threshold of £61,535/QALY. 
The majority of respondents believe ICER thresholds should be an integral part of 
HTA; however, many believe the current thresholds inadequately reflect the value of 
innovative therapies. Specifically, respondents expressed that the thresholds should 
be raised for innovative treatments in therapeutic areas lacking significant treat-
ment alternatives, as well as novel treatments for rare diseases. Additionally, 69.0% 
of respondents believe that the current level of ICER thresholds limits the availability 
of truly innovative therapies; hence a new threshold that varies by therapeutic area 
and degree of clinical unmet need should be established. CONCLUSIONS: A major-
ity of respondents support the use of health economic evaluation, but believe that 
current ICER thresholds are too low and do not accurately reflect the value of novel 
therapies. The average threshold suggested is £51,274/QALY. Respondents indicate 
that the current ICER thresholds limit patient access to truly innovative therapies.
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OBJECTIVES: The objective of this study was to identify recently launched molecules 
in Japan that were priced using the cost-plus calculation vs. cost-comparison pricing 
method and to evaluate the rationale behind their pricing decisions. METHODS: 
211 molecules assessed for pricing between March 2011 and August 2014 in Japan by 
the Ministry of Health, Labour and Welfare (MHLW) were considered in this analy-
sis. RESULTS: Of 211 molecules assessed for pricing between March 2011 and August 
2014, 71 (34%) molecules had a novel mechanism of action for their respective 
indication, while 140 (66%) did not. Of the 71 novel mechanism of action molecules, 
53 (75%) molecules underwent cost-plus pricing, while 18 (25%) underwent cost-
comparison pricing. 15 of the 18 likely underwent cost-comparison pricing either 
due to their non-differentiated clinical efficacy or similar mechanism of action 
as those of existing molecules or due to the crowdedness of the space; 3 of the 
18 underwent cost-comparison pricing due to their mechanisms of action being 
broadly defined. Of the 140 non-novel molecules, only 7 (5%) molecules were priced 
under cost-plus pricing despite not being first in class, as their comparators had 
launched 15+ years ago and were thereby deemed inappropriate for comparison 
purposes. CONCLUSIONS: The majority of novel mechanism of action molecules 
underwent cost-plus pricing. Nevertheless, a number of molecules with novel mech-
anisms of action were priced under cost-comparison pricing. Conversely, several 
non-novel molecules were priced under cost-plus pricing despite not being first in 
class. It can therefore be concluded that while the novelty of a molecule’s mecha-
nism of action serves as the main driver for determining which pricing method is 
used by the MHLW, it is not the only driver behind the decision.
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OBJECTIVES: In several countries, incremental cost-effectiveness ratio (ICER) 
“thresholds” aid in the healthcare decision-making process by helping prioritize 
the distribution of resources across interventions. The aim of the study was to 
assess the use of ICER thresholds in the P&R process, and understand the evolution 
of ICER thresholds over time. METHODS: A targeted literature review was conducted 
using search terms to address the following research questions: (i) How have ICER 
thresholds changed over time to reflect advances in medical technology? (ii) What 
is the societal willingness to pay (WTP) per QALY? (iii) How do the ICER values of 
interventions treating different diseases compare? PubMed and Grey Literature 
were searched for relevant studies published in English between January 1970 and 
September 2014. RESULTS: This review summarizes evidence from 48 studies. 
Literature revealed that countries use explicit and implicit ICER thresholds during 
the P&R process. In the US and UK, thresholds were established in 1982 and 1999 
respectively, and despite significant advances in medical technology, these have 
not been updated. Our review indicates that the estimated societal WTP in the US 
is between $109,000–$297,000/QALY, and it has been recommended that the ICER 
threshold be raised to at least $200,000/QALY. Additionally, our review shows that 
ICER values vary significantly for different therapeutic areas based on medication 
cost, unmet need, and severity. For example, the average ICER value for an interven-
tion treating Non-Small Cell Lung Cancer ($100,442/QALY) is approximately four-fold 
that of Type 2 Diabetes ($22,663/QALY). CONCLUSIONS: Researchers cite that ICER 
thresholds are dynamic, and should change over time to account for innovation in 
technology, inflation and increased research and development costs. In addition to 
end-of-life care, efforts should be made to establish different thresholds for diseases 
with high unmet needs to facilitate patient access to novel therapies.
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